209 related articles for article (PubMed ID: 36338546)
1. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe.
Martin JC; Sims JR; Gupta A; Bakin AV; Ohm JE
Cancer Res Commun; 2022 Jun; 2(6):471-482. PubMed ID: 36338546
[TBL] [Abstract][Full Text] [Related]
2. CDC7 kinase (DDK) inhibition disrupts DNA replication leading to mitotic catastrophe in Ewing sarcoma.
Martin JC; Sims JR; Gupta A; Hagoel TJ; Gao L; Lynch ML; Woloszynska A; Melendy T; Kane JF; Kuechle J; Ohm JE
Cell Death Discov; 2022 Feb; 8(1):85. PubMed ID: 35220396
[TBL] [Abstract][Full Text] [Related]
3. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
7. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
[TBL] [Abstract][Full Text] [Related]
8. FBH1 deficiency sensitizes cells to WEE1 inhibition by promoting mitotic catastrophe.
Jennings L; Walters HA; McCraw TJ; Turner JL; Mason JM
DNA Repair (Amst); 2024 Jan; 133():103611. PubMed ID: 38103522
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
10. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
11. Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition.
Soni UK; Wang Y; Pandey RN; Roberts R; Pressey JG; Hegde RS
Clin Cancer Res; 2023 Jan; 29(2):458-471. PubMed ID: 36394520
[TBL] [Abstract][Full Text] [Related]
12. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
[TBL] [Abstract][Full Text] [Related]
13. Development and Characterization of a Wee1 Kinase Degrader.
Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
[TBL] [Abstract][Full Text] [Related]
14. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
15. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M
PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417
[TBL] [Abstract][Full Text] [Related]
16. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
17. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
18. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells.
Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441
[TBL] [Abstract][Full Text] [Related]
19. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
Hauge S; Macurek L; Syljuåsen RG
Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
[TBL] [Abstract][Full Text] [Related]
20. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.
Kreahling JM; Foroutan P; Reed D; Martinez G; Razabdouski T; Bui MM; Raghavan M; Letson D; Gillies RJ; Altiok S
PLoS One; 2013; 8(3):e57523. PubMed ID: 23520471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]